IFNA2 and COVID-19: Six out seven HIV‐infected patients with IFN‐I auto‐Abs (85.7%) had auto‐Abs against both IFN‐α and IFN‐ω subtypes versus 9 out 15 (60%) of the patients with COVID‐19.